1. Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2. Department of Orthopaedics, Shenzhen People’s Hospital, The Second Medical College of Jinan University, Shenzhen 518020, China; 3. Clinical Research Center, Shenzhen People’s Hospital, The Second Hospital Medical College of Jinan University, Shenzhen 518020, China
The aim of this paper was to study the differential gene expression of giant cell tumor of bone (GCTB) by gene chip technology. Total RNA of 8 fresh GCTB specimens (Jaffe I∶6 cases, II∶1 case, III∶1 case; Campanacci I∶6 cases, II∶1 case, III∶1 case; Enneking Staging G0T1-2M0: 5 cases, G1T1-2M0: 2 cases, G1T2M0: 1 case) and 4 normal bony callus specimens (the control group) were extracted and purified to get mRNA and then reverse transcribed to complementary DNA, respectively. Microarray screening with a set of 8064 human cDNA genes was conducted to analyze the difference among the samples and the control. The hybridization signals were scanned. The gene expression disparity between the GCTB samples and normal bony callus was significantly different (P<0.01), and the disparity of over 5-fold was found in 47 genes in the GCTB specimens, with 25 genes up-regulated and 22 down-regulated including the extracellular matrix and transforming-related genes, oncogene and its homolog genes, cytokine and its receptor genes. Specific gene spectrum associated with GCTB can be identified by cDNA microarray, which will be the foundation of progressive etiology elucidation, diagnosis and treatment of GCTB.
Corresponding Author(s):
YANG Shuhua,Email:shuhuayabc@vip.sina.com
引用本文:
. Gene expression disparity in giant cell tumor of bone[J]. Frontiers of Medicine in China, 2009, 3(1): 49-56.
Xiaohua PAN, Shuhua YANG, Deming XIAO, Yong DAI, Lili REN. Gene expression disparity in giant cell tumor of bone. Front Med Chin, 2009, 3(1): 49-56.
participates in collagen catabolism, albuminolysis; collagen protease and metalloendoprotease activity
DSPG3
AA131238
Hs.435680
dermatan sulphate mucoprotein 3
regulates glycosaminoglycan binding
DPT
R48303
Hs.80552
skin pontine protein
cell adhesion and protein binding
MMP12
R92994
Hs.645661
matrix metalloproteinase 12
endometrium adenocarcinoma oncogene
COL3A1
T98612
Hs.443625
type III collagen α1
participates in formation of connective tissue like skin and pneumoangiogram, mutation leads to type IV Ehlers-Danlos syndrome
MMP9
T72581
Hs.297413
matrix metalloproteinase 9
increases expression on abdominal aortic aneurysm anterior wall
COL1A2
AA490172
Hs.489142
type I collagen α2
encodes a chain of type I collagen, variation may lead to osteogenesis imperfecta, Ehlers-Danlos syndrome, idiopathic osteoporosis, atypical arachnodactyly
COL8A2
AA780815
Hs.353001
type VIII collagen α2
endothelial corneal dystrophy related
COL5A2
AA461456
Hs.445827
type V collagen α2
encodes an α chain of low abundance collagen fiber, related with type I, II Ehlers-Danlos syndrome
CTSS
AA236164
Hs.181301
cathepsin S
family of C1 peptidase of lysosome cysteine proteinase
MMP2
AA936799
Hs.513617
matrix metalloproteinase 2
encodes the degradation of type IV collage enzyme
COL5A3
AA994760
Hs.235368
type V collagen α3
encodes an α chain of low abundance collagen fiber, related with Ehlers-Danlos syndrome
Tab.1
gene tag
GenBank
UniGene
gene name
related function
MMP3
W51794
Hs.645710
matrix metalloproteinase 3
collagen catabolism and calcium, and zinc deposition
COMP
N94385
Hs.1584
cartilage oligomer matrix protein
calcific deposit and extracellular matrix structure composition, participates in beta -TGF signal pathway, closely related with skeleton development, activity of structure molecule
COL10A1
AI828306
Hs.520339
collagen of type α1X
down-regulation will cause epiphysis dyschondroplasia, maldevelopment or dysplasia
MMP7
AA031514
Hs.2256
matrix metalloproteinase 7
degrades proteoglycans, fibronectin, elastin, casein and participates in wound healing
COL1A2
AA490172
Hs.489142
type I collagen α2
encodes a chain of type I collagen, variation may lead to osteogenesis imperfecta, Ehlers-Danlos syndrome, Idiopathic osteoporosis, atypical arachnodactyly
COL6A1
H99676
Hs.474053
type VI collagen α1
mutation may lead to autosomal dominant disorder: Bethlem myopathy
COL18A1
N81029
Hs.517356
type XVIII collagen α1
related with spinal injury
MMP15
AA443300
Hs.80343
matrix metalloproteinase 15
cell surface matrix metalloproteinase
Tab.2
gene tag
GenBank
UniGene
gene name
related function
PTTG1
AA430032
Hs.350966
hypophysin tumor transforming gene 1
participates in DNA metabolism, repair, replication and chromosomal disjunction. affects RNA polymerase 2 activity
participates in the calcium signal pathway, transmembrane receptor protein tyrosine kinase (PTK) signal pathway, related with ATP, membrane protein phosphorylation, epidermal growth factor (EGF) receptor
MNDA
N29376
Hs.153837
bone marrow nucleus differentiation antigen
participates in cell defence reaction and cell transcription regulation
PIM2
AA863383
Hs.496096
pim-2 oncogene
related to carcinoma of prostate; participates in NF-kappaB activation pathway, regulates cell survival
RB1
AA045192
Hs.408528
retinal glioblastoma factor 1
related to retinal glioblastoma, osteosarcoma
FGR
AA256172
Hs.1422
proto-oncogene tyrosine protein kinase FGR
tyrosine protein kinase Src family member, negatively regulates cell migration and adherence
Tab.3
gene tag
GenBank
UniGene
gene name
related function
PTGES
AA436163
Hs.146688
prostaglandin E synthase
participates in prostaglandin metabolism and signal transduction
TYRO3
W69497
Hs.381282
protein tyrosine kinase (PTK)
participates in protein binding, receptor activity and signal transduction, etc
HYAL1
AA464196
Hs.75619
hyaluronic acid glucosaminidase 1
participates in glucosaminidase, hydrolysis enzymatic activity somato-regulation; significant efficacy on glycon synthesis and lysosome receptor activity
ELF3
AA434373
Hs.67928
E74 like factor 3
affects formation of biphasic differentiation synovial sarcoma epithelium structure
MPP2
R60019
Hs.514208
membrane protein,palmitoylation 2
affects cytoskeleton, regulates cell proliferation and signal pathway
one of the encoding epidermal growth factor receptor family, breast carcinoma, ovarian cancer
Tab.4
gene tag
GenBank
UniGene
gene name
related function
SCYA3
AA677522
Hs.514107
small inducible cytokine A3
regulates calcium ion dynamic equilibrium and cell movement, chemotactic factor, exocytosis, inflammatory response, signal transducer
TNFRSF11B
AA194983
Hs.81791
tumor necrosis factor receptor family 11B
participates in apoptosis and skeletal development
SCYA18
AA495985
Hs.143961
small inducible cytokine A18
immunoregulation, inflammatory response related secretory protein; participates in inflammatory response
SCYA3L1
R47893
Hs.512683
small inducible A3 like cytokine 1
related with macrophage inflammatory protein
SCYB6
AI889554
Hs.164021
small inducible cytokine subunit B6
participates in neovascularization, affects tumor formation
SCYA4
H62864
Hs.655293
small inducible cytokine A4
macrophage inflammatory protein 1, lymphocyte activation
Tab.5
gene tag
GenBank
UniGene
gene name
related function
SCYD1
R66139
Hs. 6376
small inducible cytokine D1
chemotactic factor (C-X3 ligand 1), participates in immune response and calcium ion dependent cell-cell adhesion
SCYB14
W72294
Hs.483444
small inducible cytokine B14
chemotactic factor (C-X3 ligand 14)
IFNGR1
H11482
Hs.520414
γ interferon 1
participates in many kinds of immune response and signal transduction
TNFAIP2
AA457114
Hs.660676
tumor necrosis factor, α-induced protein 2
retinoic acid of target gene in acute promyelocytic leukemia (APL)
LILRB2
H54023
Hs.655652
leukocyte immunoglobulin like receptor B
controls inflammatory reaction and cytotoxicity to centralize immunological reaction; recognition of MHC molecule HLA-G
Tab.6
1
Tubbs W S, Brown L R, Beabout J W, Rock M G, Unni K K. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR , 1992, 158(3): 331-334
2
Sung H W, Kuo D P, Shu W P, Chai Y B, Liu C C, Li S M. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am , 1982, 64(5): 755-761
3
Prosser G H, Baloch K G, Tillman R M, Carter S R, Grimer R J. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res , 2005, 435(6): 211-218 doi: 10.1097/01.blo.0000160024.06739.ff
Tian B L, Wen J M, Zhang M, Xie D, Xu R B, Luo C J. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol Pathol , 2002, 55(6): 394-397 doi: 10.1136/mp.55.6.394
6
Kumta S M, Huang L, Cheng Y Y, Chow L T C, Lee K M, Zheng M H. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci , 2003, 73(11): 1427-1436 doi: 10.1016/S0024-3205(03)00434-X
7
Welford S M, Gregg J, Chen E, Garrison D, Sorensen P H, Denny C T, Nelson S F. Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. Nucleic Acids Res , 1998, 26(12): 3059-3065 doi: 10.1093/nar/26.12.3059
8
Li D P, Wang K, Dai Y, LV T Y. Gene Expression Profiling on Acute Rejected Transplant Kidneys with Microarray. J Huazhong Univ Sci Technol (Med Sci) . 2008, 28(2): 136-139
9
Logar D B, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab , 2007, 25(4): 219-225 doi: 10.1007/s00774-007-0753-0
10
Lacey D L, Timms E, Tan H L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell , 1998, 93(2): 165-176 doi: 10.1016/S0092-8674(00)81569-X
11
Kong Y Y, Feige U, Sarosi I, Bolon B, Tafuri A, MoronyS, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch E R, Van G, Nguyen L T, Ohashi P S, Lacey D L, Fish E, Boyle W J, Penninger J M. Activated T cells regulate bone loss and joint destuction in adjuvant arthritis through osteoprotegerin ligand. Nature , 1999, 402(6759): 304-309 doi: 10.1038/46303
12
Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner E F, Taniguchi T. RANKL maintaims bone homeostasis through c-Fos-dependent induction of interferon-beta.Nature ,2002, 418 (6882): 744-749 doi: 10.1038/416744a
13
Guenther R, Krenn V, Morawietz L, Dankof A, Melcher I, Schaser K D,KasperH U, Kuban R J, Ungethüm U, Sers C. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract , 2005, 201(10): 649-663 doi: 10.1016/j.prp.2005.07.005
14
Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop , 2004, 7(424): 221-226 doi: 10.1097/01.blo.0000128280.59965.e3
15
Lackman R D, Hosalkar H S, Ogilvie C M, Torbert J T, Fox E J. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res , 2005, 438(9): 123-127 doi: 10.1097/01.blo.0000180051.27961.c3
16
Lausten G S, Jensen P K, Schi?dt T, Lund B. Local recurrences in giant cell tumour of bone: long-term follow up of 31 cases. Int Orthop , 1996, 20(3): 172-176 doi: 10.1007/s002640050057
17
Ghert M A, Rizzo M,HarrelsonJ M, Scully S P. Giant cell tumor in the appendicular skeleton, Clin Orthop Relat Res , 2002, 400(7): 201-210 doi: 10.1097/00003086-200207000-00025
